Search

Ryszard J Kole

from Cambridge, MA
Age ~78
Get Report
Also known as:
Richard J Kole, Dick Kole, Rick Kole, D Kole
Related to:
John C Smithey, 39Sandra R Piller, 76Joseph Telfair, 68Adrena E Johnson, 65Denise C Carswell, 61Isaac M Wheeler, 38
Connected to:
Anne C Kole, 102Anxhela Kole, 41Ben Kole, 48Cheryl A Kole, 77David A Kole, 56Erin R Kole, 33George M Kole, 95Jonathan D Kole, 51Laura M Kole, 45Miranda L Kole, 35

Ryszard Kole Phones & Addresses

  • Cambridge, MA
  • 203 Longwood Dr, Chapel Hill, NC 27514 (919) 408-0151
  • 303 Deepwood Rd, Chapel Hill, NC 27514 (919) 918-4381
  • Birmingham, AL
  • Bellevue, WA
  • Corvallis, OR

Resumes

Resumes

Ryszard Kole Photo 1

Consultant

View page
Location:
Cambridge, MA
Industry:
Pharmaceuticals
Work:
Ercole Biotech Consulting
Consultant
Sarepta Therapeutics Feb 2012 - Aug 2016
Distinguished Scientist
Sarepta Therapeutics Apr 2008 - Feb 2012
Senior Vice President Discovery
Sarepta Therapeutics 2012 - 2012
Senior Advisor
University of North Carolina at Chapel Hill Feb 1983 - Oct 2011
Professor of Pharmacology
Education:
Institute of Biochemistry and Biophysics, Warsaw, Poland
Doctorates, Doctor of Philosophy University of Warsaw
Masters, Master of Arts, Chemistry
Skills:
Molecular Biology
Biotechnology
Project Management
Lifesciences
Patents
Pharmaceutical Industry
Intellectual Property
In Vitro
In Vivo
Languages:
English
Polish
French
Russian
Ryszard Kole Photo 2

Ryszard Kole

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ryszard Kole
Executive Vice-President, Senior Vice-President
Sarepta Therapeutics
Biotechnology · A Development Stage Company Engaged In Biopharmaceutical Preparations · Pharmaceutical Preparations · Commercial Physical Research · Nonclassifiable Establishments · Wholesale Drugs/Sundries
215 1 St, Cambridge, MA 02142
Cambridge, MA 02142
3450 Monte Villa Pkwy, Bothell, WA 98021
245 1 St, Cambridge, MA 02142
(425) 354-5038, (617) 945-2414

Publications

Us Patents

Soluble Tnf Receptors And Their Use In Treatment Of Disease

View page
US Patent:
7785834, Aug 31, 2010
Filed:
May 1, 2007
Appl. No.:
11/799117
Inventors:
Peter L. Sazani - Chapel Hill NC, US
Maria Graziewicz - Chapel Hill NC, US
Ryszard Kole - Chapel Hill NC, US
Henrik Ørum - Vaerlose, DK
Assignee:
Ercole Biotech, Inc. - Research Triangle Park NC
University of North Carolina at Chapel Hill - Chapel Hill NC
Santaris Pharma A/S - Horsholm
International Classification:
C07H 21/04
A61K 38/17
C12N 15/12
C12N 15/63
C12N 15/28
US Classification:
435 691, 536 235, 530350, 4353201, 435361, 4352523
Abstract:
The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.

Soluble Her2 And Her3 Splice Variant Proteins, Splice-Switching Oligonucleotides, And Their Use In The Treatment Of Disease

View page
US Patent:
7884194, Feb 8, 2011
Filed:
Jun 6, 2008
Appl. No.:
12/157094
Inventors:
Ryszard Kole - Corvallis OR, US
Peter Sazani - Corvallis OR, US
Jing Wan - Chapel Hill NC, US
Assignee:
AVI BioPharma Inc. - Corvallis OR
International Classification:
C07K 14/485
C12N 15/11
US Classification:
530402, 536 235, 530350
Abstract:
Soluble epidermal growth factor receptors 2 and 3 (HER2 and HER3) splice variant proteins with HER2 and HER3 antagonist activity and anti-proliferative properties, as well as the corresponding nucleic acids, are provided for treatment of proliferative diseases, in particular cancer. Also provided are compositions and methods for inducing expression of these splice variants, including splice switching oligonucleotides that modulate splicing of pre-mRNA that codes for these receptors.

Chimeric Oligomeric Compounds For Modulation Of Splicing

View page
US Patent:
8501703, Aug 6, 2013
Filed:
Aug 29, 2006
Appl. No.:
12/065250
Inventors:
C. Frank Bennett - Carlsbad CA, US
Nicholas M. Dean - Olivenhain CA, US
Ryszard Kole - Chapel Hill NC, US
Casey C. Kopczynski - Chapel Hill NC, US
Assignee:
Isis Pharmaceuticals, Inc. - Carlsbad CA
Sarepta Therapeutics - Cambridge MA
International Classification:
A61K 48/00
US Classification:
514 44, 536 245, 536 241, 536 2431
Abstract:
Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.

Stable Alteration Of Pre-Mrna Splicing Patterns By Modified Rnas

View page
US Patent:
20030036519, Feb 20, 2003
Filed:
Apr 20, 1999
Appl. No.:
09/295176
Inventors:
RYSZARD KOLE - CHAPEL HILL NC, US
DANIEL SCHUMPERLI - BUEHLSTR, CH
DANIEL SUTER - SUNNHALE, CH
International Classification:
A61K048/00
C07H021/02
US Classification:
514/044000, 536/023100
Abstract:
The present invention provides a method of upregulating expression of a protein of interest (e.g., a native protein) in a cell, the cell containing a DNA encoding the protein, which DNA contains a mutation that causes downregulation of the protein by aberrant splicing in a pre-mRNA, wherein the DNA encodes the pre-mRNA; wherein the pre-mRNA contains a native intron having a first set of splice elements, which native intron is removed by splicing when the mutation is absent to produce a first mRNA encoding the protein; and wherein the pre-mRNA further contains an aberrant intron different from the native intron having a second set of splice elements, which aberrant intron is removed by splicing when the mutation is present to produce an aberrant second mRNA different from the first mRNA. The method comprises administering to the cell a gene transfer vector a heterologous oligonucleotide in the cell, the heterologous oligonucleotide comprising a nuclear localization element joined to an antisense oligonucleotide, which antisense oligonucleotide hybridizes to the pre-mRNA in the nucleus of the cell to create a duplex thereof under conditions which permit splicing, and wherein the antisense oligonucleotide blocks a member of the aberrant second set of splice elements so that the native intron is removed by splicing and the protein of interest is produced. Vectors and oligonucleotides useful for carrying out the method are also disclosed.

Methods And Compositions For Modification Of Splicing Of Pre-Mrna

View page
US Patent:
20040137472, Jul 15, 2004
Filed:
Sep 26, 2003
Appl. No.:
10/672501
Inventors:
Ryszard Kole - Chapel Hill NC, US
International Classification:
C12Q001/68
C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
The present invention provides a method of preventing a splicing event in a pre-mRNA molecule, comprising contacting the pre-mRNA and/or elements of the splicing machinery with a small molecule compound identified according to the methods described herein to prevent the splicing event in the pre-mRNA molecule. Further provided is a method of inducing a splicing event in a pre-mRNA molecule, comprising contacting the pre-mRNA and/or elements of the splicing machinery with a small molecule compound identified according to the methods described herein to induce the splicing event in the pre-mRNA molecule. Furthermore, a method is provided herein of treating a patient having a disorder associated with an alternative or aberrant splicing event in a pre-mRNA molecule, comprising administering to the patient a therapeutically effective amount of a compound identified according to the methods described herein to prevent an alternative or aberrant splicing event in a pre-mRNA molecule, thereby treating the patient.

Splice Switch Oligomers For Tnf Superfamily Receptors And Their Use In Treatment Of Disease

View page
US Patent:
20070105807, May 10, 2007
Filed:
Nov 10, 2006
Appl. No.:
11/595485
Inventors:
Peter Sazani - Chapel Hill NC, US
Ryszard Kole - Chapel Hill NC, US
Henrik Orum - Vaerlose, DK
International Classification:
A61K 48/00
C07H 21/02
US Classification:
514044000, 536023100
Abstract:
Methods and compositions are disclosed for controlling expression of TNF receptors (TNFR1 and TNFR2) and of other receptors in the TNFR superfamily using compounds that modulate splicing of pre-mRNA encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms of the receptor which act as an antagonist to reduce TNF-α activity or activity of the relevant ligand. Reducing TNF-α activity provides a method of treating or ameliorating inflammatory diseases or conditions associated with TNF-α activity. Similarly, diseases associated with other ligands can be treated in like manner. In particular, the compounds of the invention are splice-splice switching oligomers (SSOs) which are small molecules that are stable in vivo, hybridize to the RNA in a sequence specific manner and, in conjunction with their target, are not degraded by RNAse H.

Compound And Method For Treating Myotonic Dystrophy

View page
US Patent:
20100016215, Jan 21, 2010
Filed:
Jun 26, 2009
Appl. No.:
12/493140
Inventors:
Hong M. Moulton - Corvallis OR, US
Ryszard Kole - Corvallis OR, US
Assignee:
AVI BioPharma, Inc. - Corvallis OR
International Classification:
A61K 38/14
C07K 9/00
A61P 21/00
US Classification:
514 7, 530322, 514 8
Abstract:
An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R)XB, where R is arginine; B is β-alanine; and each X is —C(O)—(CH)—NH—, where n is 4-6. The antisense compound is effective to selectively block the sequestration of muscleblind-like 1 protein (MBNL1) and/or CUGBP, in heart and quadricep muscle in a myotonic dystrophy animal model.

Multiple Exon Skipping Compositions For Dmd

View page
US Patent:
20100130591, May 27, 2010
Filed:
Oct 23, 2009
Appl. No.:
12/605276
Inventors:
Peter Sazani - Bothell WA, US
Ryszard Kole - Bellevue WA, US
International Classification:
A61K 31/7088
C07H 21/02
C07K 9/00
A61P 21/00
US Classification:
514 44 A, 536 245, 530322
Abstract:
Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
Control profile
Ryszard J Kole from Cambridge, MA, age ~78 Get Report